Arvinas - ARVN Stock Forecast, Price & News

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARVN shares.
View ARVN analyst ratings or view top-rated stocks.

17 brokerages have issued 1 year price objectives for Arvinas' stock. Their ARVN share price forecasts range from $42.00 to $102.00. On average, they expect the company's share price to reach $78.69 in the next twelve months. This suggests a possible upside of 101.9% from the stock's current price.
View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts.

Arvinas' stock was trading at $82.14 at the start of the year. Since then, ARVN stock has decreased by 52.5% and is now trading at $38.98.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our ARVN earnings forecast.

Arvinas, Inc. (NASDAQ:ARVN) posted its earnings results on Tuesday, November, 8th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.98) by $0.26. The firm earned $30.30 million during the quarter, compared to analyst estimates of $44.20 million. Arvinas had a negative trailing twelve-month return on equity of 36.12% and a negative net margin of 225.34%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.85%), BlackRock Inc. (6.96%), Bellevue Group AG (4.12%), Price T Rowe Associates Inc. MD (4.10%), State Street Corp (2.04%) and Pictet Asset Management SA (0.94%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARVN stock can currently be purchased for approximately $38.98.

Arvinas (NASDAQ:ARVN) has a market capitalization of $2.07 billion and generates $46.70 million in revenue each year. The company earns $-191,000,000.00 in net income (profit) each year or ($4.76) on an earnings per share basis.

The company employs 280 workers across the globe.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.